As we were on the topic of the slow nature of dealing with large pharmas, imo the company has a strategy that expansion of mix n go's uses into other industries will not occur in the researchable future. Considering the slow moving processes we all wait upon for confirmation of mix n go's acceptance and economic viability in diagnostics, whats to stop ADO marketing its product to other industries? most of which will not require the stringent goings-over of large pharmas.
any thoughts?
the current path
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(3.67%) |
Mkt cap ! $52.28M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $7.812K | 349.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 828094 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1102151 | 4 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ADO (ASX) Chart |